Journal
CURRENT ONCOLOGY
Volume 26, Issue 3, Pages E418-E421Publisher
MULTIMED INC
DOI: 10.3747/co.26.4381
Keywords
Melanoma; checkpoint blockade; myocarditis
Categories
Ask authors/readers for more resources
Combination immune checkpoint blockade with concurrent administration of the anti-cTLA4 antibody ipilimu-mab and the anti-PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases. That combination has also been associated with increased toxicity, including rare immune-related adverse events. Here we describe a case of fatal steroid-refractory myocarditis and panmyositis associated with the use of this combination in a patient with metastatic melanoma. Correlative studies indicated increased levels of serum interleukin 6 in this patient at the onset of toxicity, suggesting a possible role for anti-interleukin 6 receptor antibodies in the treatment of subsequent cases of this rare, but fatal, toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available